Use of certain phenyl napthyl compounds for protection of neurons and oligodendrocytes in the treatment of multiple sclerosis (MS)

Details for Australian Patent Application No. 2005323163 (hide)

Owner Aventis Pharmaceuticals Inc.

Inventors Funes, Sandrine; Wirtz-Brugger, Frederike; Petko, Wayne; Merrill, Jean; Chandross, Karen

Agent Watermark

Pub. Number AU-A-2005323163

PCT Pub. Number WO2006/073724

Priority 60/641,315 04.01.05 US

Filing date 14 December 2005

Wipo publication date 13 July 2006

International Classifications

A61K 31/05 (2006.01)

A61K 31/055 (2006.01)

A61P 25/28 (2006.01) Drugs for disorders of the nervous system

Event Publications

19 July 2007 PCT application entered the National Phase

  PCT publication WO2006/073724 Priority application(s): WO2006/073724

17 December 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005323165-Use of certain biphenyl compounds for protection of neurons and oligodendrocytes in the treatment of multiple sclerosis (MS)

2005323162-Non-combustible reinforced cementitous lightweight panels and metal frame system for flooring